ELEDON PHARMACEUTICALS INC. - COMMON STOCK

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

07 2 2025 09:00:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

29 1 2025 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

13 1 2025 06:00:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

12 11 2024 15:01:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

06 11 2024 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

29 10 2024 06:46:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

29 10 2024 06:45:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

11 9 2024 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

04 9 2024 06:00:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

14 8 2024 16:21:26 提供 Nasdaq GlobeNewswire

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

29 7 2024 06:00:00 提供 Nasdaq GlobeNewswire

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

02 7 2024 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

03 6 2024 15:01:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

09 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

09 5 2024 06:00:01 提供 Nasdaq GlobeNewswire

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

07 5 2024 06:05:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

07 5 2024 06:00:01 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

28 3 2024 15:01:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

25 3 2024 15:56:42 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

21 3 2024 09:31:12 提供 Nasdaq GlobeNewswire